Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on November 25, 2024. The filing reports a material corporate action involving a reverse stock split and amendments to the Company's Articles of Incorporation, effective November 25, 2024.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on capital structure changes rather than operational financial performance.
Material Changes
- Reverse Stock Split: A 1-for-25 reverse stock split of issued and outstanding common stock was effected.
- Authorized Shares: The total number of authorized shares of Common Stock was decreased from 400,000,000 to 16,000,000 shares.
- Par Value: The par value per share remains unchanged at $0.001.
- Trading Details: The stock began trading on a split-adjusted basis on November 26, 2024, under the symbol "CTXR" with a new CUSIP number (17322U306).
- Adjustments: Outstanding warrants, stock options, and equity incentive plans were proportionately adjusted for the split ratio.
Outlook, Risks, and Management Commentary
Purpose: The reverse stock split is intended to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share for continued listing.
Fractional Shares: No fractional shares will be issued; fractional shares resulting from the split will be rounded up to the nearest whole share at the participant level.
Risks: The filing does not explicitly detail new risks beyond the implication that the Company was previously at risk of delisting due to non-compliance with minimum bid price requirements.
Key Facts for Investor Verification
- Verify the post-split share count and the new CUSIP number (17322U306) in brokerage accounts.
- Confirm the adjusted exercise prices for any held warrants or stock options.
- Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for continued Nasdaq listing.
- Review the full text of the Certificate of Change (Exhibit 3.1) for complete legal details.